4/A: Tonix Pharmaceuticals CEO Amends Beneficial Ownership Statement to Correct Stock Option Exercise Price
SEC Form 4/A (Amendment to Statement of Changes in Beneficial Ownership)
Seth Lederman, CEO of Tonix Pharmaceuticals, files an amendment to a previous statement to correct the exercise price of stock options granted on February 27, 2024.
Summary
- Seth Lederman, the CEO of Tonix Pharmaceuticals Holding Corp., filed an amendment to a Form 4, initially filed on February 29, 2024, regarding changes in beneficial ownership.
- The amendment, dated March 6, 2024, corrects the conversion or exercise price of certain stock options granted on February 27, 2024.
- Specifically, the exercise price for a stock option grant of 1,309,911 shares was corrected from $0.0368 to $0.368.
- The filing also details the acquisition of stock options with exercise prices of $0.368 and $0.46, vesting schedules, and expiration dates.
Sentiment
Score: 7
Explanation: The document is a routine correction of a regulatory filing. It doesn't inherently indicate positive or negative sentiment, but accuracy in reporting is generally viewed favorably.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of stock option grant and transactions. |
| 02/29/2024 | Date of original Form 4 filing. |
| 03/06/2024 | Date of amended Form 4 filing. |
| 08/27/2024 | First possible vesting date for some options. |
| 02/27/2025 | First anniversary of issuance for vesting purposes. |
| 02/27/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.